ArticleJournal of pediatric gastroenterology and nutrition2026
Real-world data on STRIDE-II treatment targets in a pediatric cohort with inflammatory bowel disease.
Article in Journal of pediatric gastroenterology and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Switching Between Anti-TNFs and Other Biologic Drugs in Paediatric Inflammatory Bowel Disease: A Narrative Review and Practical Clinical Guide.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesSTRIDE (selecting therapeutic targets in inflammatory bowel disease) established evidence-based targets for treat-to-target strategies in inflammatory bowel disease (IBD). STRIDE-II designates clinical remission, C-reactive protein (CRP) normalization, and fecal calprotectin (FC) reduction as short- to intermediate-term targets, and mucosal healing as a long-term target. This study evaluated STRIDE-II application and disease control in a real-world pediatric cohort.
methodsWe retrospectively analyzed newly diagnosed pediatric IBD patients (ages 3-18 years) treated according to guidelines between June 2017 and January 2023. Time-to-reach STRIDE-II targets and time-to-first flare were assessed over 52 weeks using disease activity indices, inflammatory biomarkers (CRP, FC), and endoscopy.
resultsSeventy-four patients were included (37 Crohn's disease [CD], 37 ulcerative colitis [UC]). All CD patients received primary maintenance therapy with immunomodulators or biologics, versus 51% UC patients. Clinical remission and CRP normalization occurred within 5-10 weeks; FC normalization within 12-19 weeks. By 6 months, combined targets (clinical remission plus CRP and FC normalization) were achieved by 54% of CD patients and 43% of UC patients. Clinical relapse after remission occurred more frequently in UC than in CD (67% vs. 43%, p = 0.0334). Follow-up endoscopy at a median of 41 weeks (CD) and 52 weeks (UC) showed endoscopic healing in 7/18 (39%) CD and 13/22 (59%) UC patients.
conclusionsMost pediatric IBD patients achieved clinical remission and CRP normalization within STRIDE-II timeframes, whereas FC normalization occurred later, and relapses-particularly in UC-remained common. The notable proportion of patients with suboptimal disease control underscores the need for continuous monitoring in pediatric IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.